FY2024 Earnings Forecast for Alumis Issued By HC Wainwright

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Alumis in a research note issued on Thursday, November 14th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($9.75) per share for the year, up from their prior forecast of ($11.42). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Alumis’ Q4 2024 earnings at ($1.39) EPS, Q1 2025 earnings at ($1.40) EPS, Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.45) EPS and FY2025 earnings at ($5.68) EPS.

ALMS has been the subject of several other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Leerink Partners assumed coverage on Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 target price for the company. Guggenheim began coverage on Alumis in a report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price target on the stock. Baird R W raised Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Finally, Leerink Partnrs raised Alumis to a “strong-buy” rating in a research report on Tuesday, July 23rd. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $26.83.

Alumis Stock Up 19.8 %

Shares of ALMS stock opened at $10.35 on Monday. Alumis has a fifty-two week low of $8.23 and a fifty-two week high of $13.53. The company has a 50 day simple moving average of $11.16.

Institutional Investors Weigh In On Alumis

Several institutional investors have recently added to or reduced their stakes in ALMS. Barclays PLC acquired a new stake in Alumis during the third quarter worth approximately $197,000. Geode Capital Management LLC acquired a new stake in Alumis during the 3rd quarter worth $3,266,000. State Street Corp acquired a new stake in Alumis during the 3rd quarter worth $866,000. Stifel Financial Corp purchased a new stake in Alumis in the third quarter valued at $931,000. Finally, Samsara BioCapital LLC acquired a new position in Alumis in the third quarter valued at $34,886,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.